About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles

Antiplatelet and Lipid-lowering Drugs in Hypertension

Citation:

European Cardiology Review 2014;9(1):16–20

Targeting Two Sources of Cholesterol - An Advanced Treatment Approach to Lipid-lowering Management

Citation:

European Cardiology 2005;1(1):16-7

How Do We Approach Low High-density Lipoprotein Cholesterol in 2011?

Citation:

European Cardiology 2011;7(4):257–63

Managing Dyslipidaemic Patients - Improving Adherence with Lifestyle Intervention

Citation:

European Cardiology 2011;7(4):246–50